Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cibus, Inc.
Report date July 01, 2020 · Filed August 03, 2020
Section 16 reporting ended · disclosed 2020-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130,815 |
Reported balance
After 2020-07-01 transaction · row 1
1 source rowRow 1 · 2020-07-01 · Sale · Disposed 4,228 · Balance 130,815 F1: The price reported in Column 4 is a weighted average. The shares were sold in multiple transactions at prices ranging from $4.55 to $4.87, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average. The shares were sold in multiple transactions at prices ranging from $4.55 to $4.87, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2020 Filed Aug 3, 2020 21:13 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,228 | $4.65 | $19,647.09 |
DisclosureSEC source: 0001615594-20-000047 · primary_doc.xml · nonDerivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,815 F1 · price: The price reported in Column 4 is a weighted average. The shares were sold in multiple transactions at prices ranging from $4.55 to $4.87, inclusive. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:23 UTC | Cibus, Inc. CLXT · Entity 6658 | Tax withholdingCommon Stock | 3,690 | $2.95 | $10,902.84 |
DisclosureSEC source: 0001615594-20-000021 · primary_doc.xml · nonDerivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,043 Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 21:22 UTC | Cibus, Inc. CLXT · Entity 6658 | Tax withholdingCommon Stock | 15,715 | $12.90 | $202,723.50 |
DisclosureSEC source: 0001615594-19-000023 · primary_doc.xml · nonDerivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,733 Read SEC document |
| May 15, 2019 Filed May 17, 2019 22:48 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001127602-19-019054 · form4.xml · derivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2029-05-15 F1 · derivative.exercise_date: The stock options to purchase shares of Calyxt, Inc. common stock ("Stock Options") were granted on May 15, 2019 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (commencing on September 30, 2021). Read SEC document |
| May 06, 2019 Filed May 9, 2019 00:48 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001127602-19-017808 · form4.xml · derivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-05-06 F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 18:38 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 2,352 | $19.49 | $45,840.48 |
DisclosureSEC source: 0001127602-18-021028 · form4.xml · nonDerivative · entry 1 Choulika Andre · CIK 0001712190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,448 F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2 · balance_after: Includes 133,280 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 23,520 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.